All In Biotech

NDA 050708 · Astellas

Prograf

Tacrolimus · Oral

NovelPriority reviewOrphan

Last checked: Nov 19, 2026Latest source record: Sep 14, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

1994

Apr 8, 1994

Approved uses

7

Original approval plus efficacy supplements

Registered trials

1,405

234 Phase 3, 122 recruiting

FAERS reports

155,512

139,657 serious, 25,602 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

Boxed warning

WARNING: MALIGNANCIES AND SERIOUS INFECTIONS Increased risk for developing serious infections and malignancies with PROGRAF or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 ) WARNING: MALIGNANCIES AND SERIOUS INFECTIONS See full prescribing information for complete boxed warning. Increased risk for developing serious infections and malignancies with PROGRAF or other immunosuppressants that may lead to hospitalization or death. ( 5.1 , 5.2 )

What it is approved for

From the label in effect Aug 25, 2023.

PROGRAF is a calcineurin-inhibitor immunosuppressant indicated for the prophylaxis of organ rejection in adult and pediatric patients receiving allogeneic liver, kidney, heart, or lung transplants, in combination with other immunosuppressants. ( 1.1 ) 1.1 Prophylaxis of Organ Rejection in Kidney, Liver, Heart, or Lung Transplant PROGRAF ® is indicated for the prophylaxis of organ rejection, in adult and pediatric patients receiving allogeneic kidney transplant [see Clinical Studies ( 14.1 )], liver transplant [see Clinical Studies ( 14.2 )], heart transplant [see Clinical Studies ( 14.3 )], or lung transplant [see Clinical Studies ( 14.4 )] in combination with other immunosuppressants.

Mechanism: Tacrolimus binds to an intracellular protein, FKBP-12. A complex of tacrolimus-FKBP-12, calcium, calmodulin, and calcineurin (a ubiquitous mammalian intracellular enzyme) is then formed, after which the phosphatase activity of calcineurin is inhibited. Such inhibition prevents the dephosphorylation and translocation of various factors such as the nuclear factor of activated T-cells (NF-AT), and nuclear factor kappa-light-chain enhancer of activated B-cells (NF-κB). Tacrolimus inhibits the expression and/or production of several cytokines that include interleukin (IL)-1 beta, IL-2, IL-3, IL-4,...

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 16, 2021 Supplement 53 · Efficacy · priority review OrphanLabelLetterReview
  • May 19, 2009 Supplement 27 · Efficacy ReviewOtherLetter
  • Mar 29, 2006 Supplement 24 · Efficacy Letter
  • Dec 1, 2000 Supplement 13 · Efficacy Label
  • Apr 22, 1997 Supplement 8 · Efficacy
  • Apr 22, 1997 Supplement 7 · Efficacy
  • Apr 8, 1994 Original approval · Type 1 - New Molecular Entity · priority review Review
3 products under this application
  • PROGRAF · TACROLIMUS EQ 0.5MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • PROGRAF · TACROLIMUS EQ 1MG BASE · CAPSULE, ORAL · Prescription · TE AB
  • PROGRAF · TACROLIMUS EQ 5MG BASE · CAPSULE, ORAL · Prescription · TE AB

Clinical trials

Interventional ClinicalTrials.gov studies with "Tacrolimus" as an intervention, any sponsor and status, largest first.

All 1,405 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • off label use15,345
  • drug ineffective10,482
  • product use in unapproved indication6,396
  • drug interaction6,373
  • acute kidney injury6,111
  • diarrhoea5,893
  • transplant rejection4,902
  • death4,875
  • pyrexia4,864
  • cytomegalovirus infection4,599
  • pneumonia4,567
  • toxicity to various agents3,914

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
2004699
2005875
2006913
20071,485
20081,997
20092,169
20102,343
20113,918
20124,663
20133,853
20144,552
20155,030
20166,022
20178,087
201810,994
201910,666
202012,133
202111,473
202211,897
202313,254
202414,306
202514,189
20269,986

Recalls

1 FDA enforcement reports for this application.

  • Dec 23, 2024 · Class I · Ongoing

    Failed Tablet/Capsule Specifications: Bottles shipped to the USA may contain empty capsules

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Part D: Prograf* (Tacrolimus)

2024 spending

$4.0M

Beneficiaries

865

4,634 claims

Per beneficiary

$4,625

$5.93 per unit

View as table
YearSpending
2020$7,621,148
2021$6,440,835
2022$5,538,435
2023$4,911,768
2024$4,000,824

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 2,856 on PubMed

Sponsor: Astellas

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.